ISRCTN16827947已完成4 期
Randomised controlled trial of the short term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31791384 protocol (added 04/12/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •Current participant inclusion criteria as of 22/01/2021:
- •1. Male, aged between 16 and 25 years
- •2. English speaking
- •3. Able to provide informed consent (understand the information sheet and make an informed decision taking into account pros and cons of study participation)
- •4. Meet clinical diagnostic criteria for DSM-5 ADHD: 5 or more current symptoms of ADHD in either the inattentive or hyperactive-impulsive symptom domains; 6 or more symptoms of ADHD in either the inattentive or hyperactive/impulsive symptom domains before the age of 12 years; Where it is not possible to gain sufficient clinical information to score childhood symptoms of ADHD, the operational criteria will be adapted to include evidence of several ADHD symptoms with impairment starting before the age of 12 years, and 5 or more symptoms currently with moderate to severe impairment
- •5. Persistent trait like (non-episodic) course of symptoms
- •6. Impairments in two or more clinical or psychosocial domains and two or more settings from symptoms of ADHD
- •7. Onset of symptoms before the age of 12 years
- •Previous participant inclusion criteria:
- •1. Male, aged between 16 and 25 years
- •2. English speaking
- •3. Able to provide informed consent (understand the information sheet and make an informed decision taking into account pros and cons of study participation)
- •4. Meet clinical diagnostic criteria for DSM-5 ADHD: 5 or more current symptoms of ADHD in either the inattentive or hyperactive-impulsive symptom domains; 6 or more symptoms of ADHD in either the inattentive or hyperactiveimpulsive symptom domains before the age of 12 years; Where it is not possible to gain sufficient clinical information to score childhood symptoms of ADHD, the operational criteria will be adapted to include evidence of several ADHD symptoms with impairment starting before the age of 12 years, and 5 or more symptoms currently with moderate to severe impairment
- •5. Persistent trait like (non-episodic) course of symptoms
- •6. Impairments in two or more clinical or psychosocial domains and two or more settings from symptoms of ADHD
- •7. Onset of symptoms before the age of 12 years
排除标准
- •Current participant exclusion criteria as of 22/01/2021:
- •1. Lack of capacity to give informed consent
- •2. Moderate or severe learning disability, defined as an IQ <60
- •3. Serious risk of violence to the researcher
- •4. Current major depression, psychosis, mania or hypomania
- •5. Past history of bipolar disorder or schizophrenia (such as those with a clear history of episodic mania/hypomania or psychosis unrelated to acute drug intoxication. Excluding chronic emotional dysregulation such as irritability, frustration, anger or emotional-mood instability)
- •6. Medical contraindications to the use of stimulants (e.g. glaucoma, hypertension, cardiovascular disease or structural heart problem)
- •7. Drug-seeking behaviour or craving (defined as drug-seeking behaviour that is unusually severe and likely to affect the titration protocol due to unusual and excessive demands for drugs; or where there is a current withdrawal syndrome from an addition disorder with drug dependency)
- •8. Taking contraindicated medication (e.g. Clonidine, Courmarins, Monoamine oxibase inhibitors, Moclobemide, Rasagline) during the four weeks prior to randomisation
- •9. Receiving any ADHD medication between consent for screening and randomisation
- •Previous participant exclusion criteria:
- •1. Lack capacity to give informed consent
- •2. Moderate or severe learning disability, defined as IQ<60
- •3. Serious risk of violence to the researcher
- •4. Current major depression, psychosis, mania or hypomania
- •5. Past history of bipolar disorder or schizophrenia
- •6. Medical contraindications to the use of stimulants (e.g. glaucoma, hypertension, cardiovascular disease or structural heart problem)
- •7. Drug seeking behaviour or craving
研究者
相似试验
进行中（未招募）
3 期
A randomised controlled trial to evaluate the cost effectiveness of prescribing high concentration fluoride toothpaste to prevent tooth decay in older adultsOral HealthDental CariesISRCTN11992428Manchester University NHS Foundation Trust1,161
已完成
不适用
A study to examine health effect indicators when a smoker switches to using a tobacco heating productISRCTN81075760British American Tobacco (Investments) Ltd506
已完成
不适用
The effectiveness of bridging from emergency to regular contraceptioReproductive healthPregnancy and ChildbirthISRCTN70616901niversity of Edinburgh636
已完成
不适用
EEPIC: Enhancing employability through positive interventions for increasing career potential. A high support career guidance intervention to improve the well-being and employability of the long term unemployed in IrelandISRCTN16801028Maynooth University120
已完成
不适用
MAGENTA: Managed activity graded exercise in teenagers and pre-adolescentsTopic: ChildrenSubtopic: All DiagnosesDisease: All DiseasesNervous System DiseasesPaediatric chronic fatigue syndrome, myalgic encephalomyelitis (CFS/ME)ISRCTN23962803Royal National Hospital for Rheumatic Disease (UK)237